A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Obesity
In brief
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Key facts
- Study ID
- NCT07142707
- Run by
- MBX Biosciences
- People needed
- 124
- Starts
- 2025-09-03
- Expected to finish
- 2026-10-30
- Last updated by the study team
- 2026-06-09
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age of >18 to ≤65 years at the time of signing the informed consent.
- Has a BMI of ≥30 to <50 kg/m2 at screening and baseline.
- Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.
You may not qualify if…
- History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
- History of currently active pancreatitis, type I and type II diabetes.
- Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.
- A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Where it is running
- MBX Biosciences Investigational Site — Doral, Florida, United States (enrolling)
- MBX Biosciences Investigational Site — Lexington, Kentucky, United States (enrolling)
- MBX Biosciences Investigational Site — Kansas City, Missouri, United States (enrolling)
- MBX Biosciences Investigational Site — Knoxville, Tennessee, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.